These data were confirmed by immunoblotting of caspase-3 (Figure 5C), which showed the appearance of the activated caspase-3 fragment and the corresponding decrease of pro-caspase-3 after MG treatment. This evidence concerns the gene CASP3 and myasthenia gravis.